Recent Pfizer Press Releases

  • 3/26/07 4:30 pm EDT

    Lipitor is the Only Statin to Have Been Studied Solely in Patients with Recent Stroke or Mini-stroke

    NEW ORLEANS--(BUSINESS WIRE)--Pfizer announced today that Lipitor® (atorvastatin calcium) Tablets 10 mg provided a significant 61 percent reduction in stroke in patients with type 2 diabetes and metabolic syndrome but without heart disease. In a separate study, patients who had suffered a recurrent stroke or mini-stroke during the trial had a significant 53 percent reduction in the risk of major coronary events (death from cardiac causes, heartmore...
  • 3/26/07 11:27 am EDT

    New Results Build on Previous Data that Lipitor is the Only Statin to Show an Impact in Head-To-Head Imaging Trials

    Separate Analysis Shows Lipitor Cuts the Risk of Coronary Events by Half in Recurrent Stroke Patients

    NEW ORLEANS--(BUSINESS WIRE)--Pfizer said today that results from two new imaging trials showed that higher dose Lipitor stopped the progression of atherosclerosis in patients with coronary heart disease or familial hypercholesterolemia (FH). The trials, which were designed to investigate the efficacy of the former investigational compound torcetrapib in combination with Lipitor compared to Lipitor alone, were presented today at the annual meeting ofmore...
  • 3/23/07 5:01 pm EDT
    NEW YORK--(BUSINESS WIRE)--In response to an announcement today by Mylan Laboratories that it has launched a generic competitor to Norvasc, Pfizer said it is making available its own generic amlodipine besylate product immediately through the company’s Greenstone subsidiary. Norvasc also will remain available to patients. Pfizer said it will continue to pursue all available legal remedies to protect the market for Norvasc through a six-more...
  • 3/23/07 10:14 am EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer announced today that new data regarding the effect of Lipitor (atorvastatin calcium) on atherosclerosis, cardiovascular events such as heart attacks and strokes, and health economics will be presented next week at the American College of Cardiology annual meeting in New Orleans. Atherosclerosis Imaging Trials Three large imaging studies compared Pfizer’s former investigational compoundmore...
  • 3/22/07 1:59 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today that the Court of Appeals for the Federal Circuit has issued a decision reversing a lower court ruling upholding the company’s U.S. patent covering amlodipine besylate, the active ingredient in Norvasc. Pfizer is reviewing the decision and is considering all its options, including seeking reconsideration. Generic manufacturer Apotex filed the appeal after a lowermore...
  • 3/20/07 3:36 pm EDT
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a federal court in the District of New Jersey (Newark) has upheld the three main U.S. patents covering Celebrex, the company’s selective non-steroidal anti-inflammatory (NSAID) medicine used to treat pain and inflammation. The patents had been challenged by generic manufacturer Teva Pharmaceuticals USA. Judge John C. Lifland ruled that the patents (Nos. 5,466,823; 5,563,165more...